Article

Rituximab in a patient with ankylosing spondylitis with demyelinating disease: A case report and review of the literature

Clinical Rheumatology
DOI: 10.1007/s10067-012-2002-8
13Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab. © Clinical Rheumatology 2012.

Author supplied keywords

Cite

CITATION STYLE

APA

Omair, M. A., Alnaqbi, K. A., & Lee, P. (2012, August). Rituximab in a patient with ankylosing spondylitis with demyelinating disease: A case report and review of the literature. Clinical Rheumatology. https://doi.org/10.1007/s10067-012-2002-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free